Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
GL-ONC1 expanded access is for patients who are ineligible for an ongoing GL-ONC1 clinical trial. Expanded access is intended to treat individual patients with advanced stage cancers, including blood cancer, with no standard of care options for treatment. Potential patients will be evaluated individually depending on GL-ONC1 product supply.
Condition or disease
Advanced Stage Cancer (Solid Tumor Disease for 4 Patients)Acute Myeloid Leukemia (6 Patients)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
21 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Diagnosis of advanced cancers with no standard of care option for treatment.
Willing and able to provide written, signed informed consent.
Use of adequate contraception.
Negative pregnancy test.
Have not recovered from severe adverse events from prior therapy.
Major surgery occurred within 28 days prior to treatment.
Known immune system disorders such as HIV, or active hepatitis B or C infection.
Clinically significant cardiac disease (New York Heart Association Class III or IV).
Have received prior therapy with an oncolytic virus of any type.
Be receiving antiviral agent active against vaccinia virus (e.g., cidofovir, vaccinia immunoglobulin, imatinib, ST-246).
Have known allergy to ovalbumin or other egg products.
Have clinically significant dermatological disorders (e.g., eczema, psoriasis, or any unhealed skin wounds or ulcers) as assessed by the treating physician.